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Abstract
We used data collected as part of the Universal Data Collection (UDC) surveillance project in
haemophilia treatment centers (HTC) to study the incidence, risk factors, and impact of septic
arthritis among males with haemophilia. Patients participating in UDC on 2 or more occasions
were included. Cases were defined as patients with documented joint infection. Characteristics of
the cases were compared with those of haemophilia patients without infection. Among the 8026
eligible patients with 36,015 person-years of follow-up, 30 (0.37%) had a documented joint
infection (incidence rate 83 per 100,000 person-years). In a logistic regression model, only
increasing age (OR = 6.1 for age ≥30), race/ethnicity other than white (OR = 3.9), presence of
inhibitor (OR = 3.9), invasive procedure in the past year (OR = 2.7) and presence of one or more
target joints (OR = 3.2) remained statistically significant. CVAD use and HCV and HIV infection
were not associated with septic arthritis risk after adjusting for potential confounders. Study
limitations include possible underestimation of septic arthritis rate in this population and its
retrospective design. We conclude that septic arthritis is an uncommon complication of
haemophilia occurring primarily in joints most affected by bleeding and reparative surgical
interventions.
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The incidence of septic arthritis in the general population is approximately 2–6 cases per
100,000 population per year and most commonly affects young children and the elderly [1,
2]. Infection in a joint is usually seeded hematogenously, and the most frequent causative
organisms are Staphylococcal and Streptococcal species. Predisposing factors include
underlying joint and connective tissue disease (e.g., rheumatoid arthritis), the presence of a
joint prosthesis, previous joint surgery, immunosuppression, and diabetes [2, 3].
Septic arthritis is more common in patients with haemophilia than the general population
and is associated with considerable morbidity including loss of range of motion in the
affected joint and, among patients with a prosthesis, removal of the artificial joint [4, 5].
Over the last 2 decades, a number of published case reports and series have implied that the
incidence of septic arthritis among people with haemophilia may have increased with the
appearance of human immunodeficiency virus (HIV) infection [4, 6–9] and increased use of
central venous access devices (CVAD) for prophylaxis [10, 11]. Moreover, the overall rate
of prosthetic joint infection after arthroplasty in haemophilia patients (especially if HIV
positive) has been reported to be much higher than that reported in the non-haemophiliac
population [5, 12, 13]. However, considerable uncertainty remains in the literature about the
incidence of and risk factors for septic arthritis in haemophilia because of differences in
study design and variations in the populations studied.
The Universal Data Collection (UDC) project, a voluntary surveillance program involving
136 federally funded haemophilia treatment centers (HTCs) in the United States, was
established in 1998 to monitor the safety of treatment products and to collect a uniform set
of clinical treatment and outcomes data that could be used to inform activities directed at
preventing complications of bleeding disorders [14, 15]. Data have been collected from
more than 18,000 people with bleeding disorders who receive care in these centers. The goal
of this study was to use data from this large database to describe the incidence of and risk
factors for joint infections and to evaluate the impact of septic arthritis on joint function
among males with haemophilia.
METHODS
The details of eligibility and recruitment for the UDC project have been reported previously
[16]. Briefly, persons with bleeding disorders are enrolled in UDC, and a standardized set of
clinical data and plasma specimen are collected each year at participating HTCs.
Participation is voluntary, and patients (or parents of minor children) are required to give
informed consent. The study has received approval from the Human Subjects Institutional
Review Boards of CDC and all participating HTCs. This report is based on data obtained
from males with haemophilia A or B.
Data collection
Demographic, treatment, and clinical outcome data were collected from UDC participants
during the annual comprehensive care visit. Date of birth was used to calculate age. Subject
race and ethnicity, based on participant self-report, was categorized in accordance with
census reporting. Haemophilia severity was based on the percentage of normal clotting
factor activity and categorized as mild if the deficient factor activity was 6 – 30 IU/ml,
moderate if 1 – 5 IU/ml, and severe if less than 1 IU/ml of a normal reference range.
Clinic records were used to determine if the participant had health insurance and to identify
the treatment regimen used. If the person infused clotting factor on a regular basis (e.g.,
every other day) to prevent bleeding, and the infusions were expected to continue
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indefinitely, he was considered to be on prophylaxis treatment. Data on the placement of a
long-term CVAD for factor infusion and any complications (e.g., infections) occurring in
these devices were also obtained from clinic records.
Participants with a measured inhibitor titer (to FVIII or FIX) of more than 0.5 Bethesda
Units at any time during the year before the comprehensive care visit were classified as
having an inhibitor. As part of the UDC project, a blood specimen is tested annually for
serologic evidence of infection with HIV and hepatitis C (HCV). The results of this testing
were used to determine the patient's status at baseline with regard to these infections.
UDC participants are routinely instructed to keep a log of all bleeds that occur between
clinic visits, including its severity, location and treatment. HTC staff review available logs
and record on the data form the number of bleeds by site (joint, muscle, or other) during the
6-month period before the comprehensive care visit. For participants who do not submit a
complete log (approximately 75% of subjects), information about bleeding is based on
patient and/or parent recall.
During the visit, the participant's height and weight were measured and used to calculate
body mass index (BMI). Thirteen measurements of range of motion (ROM) were assessed
bilaterally at the hips, knees, shoulders, elbows and ankles by a physical therapist or other
trained health care provider using a standard goniometer according to detailed guidelines
provided in a reference manual and training video supplied by CDC. ROM was not
measured in joints in which a bleed had occurred within 24 hours or whose motion was
restricted for another medical reason (e.g., recent surgery, presence of an immobilization
device such as a splint or brace).
A joint in which recurrent bleeding had occurred on 4 or more occasions during the 6
months before the clinic visit was designated a target joint. Clinic and hospital records were
reviewed to determine whether or not orthopedic surgery had been performed on 1 or more
joints during the previous year, including arthrodesis (joint fusion), synovectomy (surgical
or radioisotopic), and arthroplasty (joint replacement).
Study design
We used surveillance data collected during multiple visits on patients receiving care in
HTCs in two types of analyses. The first, a retrospective cohort analysis, used data from all
visits to calculate an overall incidence rate of septic arthritis. The second, a nested case-
control analysis to investigate the risk factors associated with septic arthritis, used data
collected only at the visits before and after the joint infection for the cases and data collected
only at the two most recent visits for the controls. Baseline characteristics of all cases used
data collected during the UDC visit before the visit when the joint infection was reported.
Baseline characteristics for the controls were based on data collected at the visit prior to the
most recent visit in the database.
Possible septic arthritis cases were identified on the basis of an affirmative response to the
question “Has the patient had a joint infection during the past year”. To verify these
surveillance data, a second questionnaire was sent to the participating HTC center as part of
the current study to confirm the case status and to collect additional information about the
infection, including diagnostic methods, causative organism(s), and treatment. In addition,
data were collected about previous surgery or procedures involving the infected joint, the
presence of a prosthetic joint or central venous access device (CVAD), the occurrence of
any preceding joint hemorrhage or trauma, and any recent history of dental or urologic
procedures.
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Based on data from the second survey, cases were confirmed to have had a joint infection
only if they had a microbial overgrowth on cultures of either synovial fluid aspirate or fluid
drainage from the affected joint, or a positive blood culture with clinical symptoms of
infection in a joint (e.g., fever, swelling, pain, tenderness, and increased warmth). All
potential cases that could not be thus confirmed were included in the control group.
Data analysis
Joint infection rates were calculated by dividing the number of joint infections by the
number of person-years of follow-up and reported as cases per 100,000 person-years. Each
visit for a patient was counted as one person-year because the data collection tool asked
about any joint infections that had occurred during the year prior to the visit. All UDC visits
for controls and all visits until the index visit for cases were included in the calculation of
person-years.
Differences in the distribution of demographic and clinical characteristics between the cases
and controls were examined for statistical significance using chi-square tests. Logistic
regression was used to identify independent risk factors for joint infection. All studied risk
factors were entered into the regression model, and variables that were not statistically
significant were removed one at a time until the most parsimonious model was achieved.
To compare changes in joint ROM before and after the joint infection, we first calculated an
overall joint index for each participant, which was the sum of all flexion and extension
(including hyperextension) measurements taken on all 10 joints. The total amount of joint
ROM limitation in degrees was calculated as the difference between the normal overall joint
index value [17] and the participant's overall joint index. The percent overall joint ROM
limitation was determined for each person by dividing his total amount of joint ROM
limitation by the normal overall joint index value and multiplying by 100. For the cases, the
change in percent ROM limitation was calculated by subtracting the limitation at the visit
during which the joint infection was reported from that measured at the baseline visit. For
controls, the change between the 2 most recent visits was calculated. Using multiple linear
regression analysis, the average change among cases was compared with that among
controls adjusting for differences in BMI, haemophilia severity, race/ethnicity, presence of
target joint, history of recent invasive surgery, and the presence of an inhibitor. All analyses
were performed using SAS Version 9 statistical software (SAS Institute, Cary, NC).
RESULTS
Between January 1, 1999, and June 30, 2005, 8950 males with haemophilia participated in
the UDC project. Of those, 8026 (90%) had 2 or more UDC visits with a cumulative 36,015
person-years of follow-up; these individuals formed the study population. Among the 114
patients whose data forms initially indicated the occurrence of a joint infection during the
year before the UDC visit, 30 (26 %) were confirmed to have had a documented joint
infection and were designated as cases. Of the remaining 84 patients, data about joint
infections were incorrectly coded on the original data collection form for 20 (24%) and
review of medical and clinic records by HTC staff in response to the second survey found no
objective evidence of joint infection for the remaining 64 patients. These 84 patients and the
remaining 7912 patients formed the control group.
The knee was the most commonly affected joint occurring in 67% of the patients and 3
(10%) patients had more than one joint infected at the time of presentation (Table 1 and
appendix 1). The diagnosis of a joint infection was confirmed by a positive culture from a
joint aspirate or fistula drainage in 83% of cases and gram positive organisms were
identified in 77% of those cases. Twelve (40%) patients had experienced hemarthrosis in the
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joint within 2 weeks of presentation with a septic arthritis. Two (6.7%) patients had either
joint aspiration or trauma of the affected joint within two weeks of the joint infection.
Eighteen patients (60%) had prior surgery in the affected joint, of which 13 (72%) were
arthroplasties. The median duration from joint arthroplasty to joint infection was 60 months
(range 1–216 months). Ten of these 13 (77%) individuals underwent surgical removal of the
infected prosthesis. Of the 8 patients with multiple prosthetic joints, 2 had concurrent
infections in more than one prosthetic joint. The median duration of antibiotic therapy was
42 days (range 5–918). Six individuals (20%) subsequently developed a recurrent joint
infection.
The overall incidence rate of joint infections for the 7-year period was 83 cases per 100,000
person-years and varied from 26 to 129 cases per 100,000 person-years annually. Participant
demographic and clinical characteristics by case-control status are shown in Table 2. The
average age of study subjects was 23.3 years, 80% had haemophilia A, and the proportions
of participants with mild, moderate, and severe haemophilia were 21%, 22%, and 57%,
respectively. Two thirds of the subjects were white, 13% were black, 12% were Hispanic,
and the rest were other races. A significantly higher proportion of cases than controls were
older, non-white, and on home infusion and were more likely to have severe haemophilia,
non-traditional or no health insurance, an inhibitor, a higher frequency of joint bleeds, at
least one target joint, and a recent invasive procedure. In addition, cases were more likely
than controls to be HIV and HCV positive.
When all of the patient characteristics were examined in a multivariate model, several were
independently associated with case status (Table 3). Cases were 6.0 times more likely to be
30–39 years old and 9.4 times more likely to be 40 years or older than they were to be
younger than 30 years of age. Cases were also 3.9–5.0 times more likely to be some other
race or ethnicity besides white. Finally, cases were 2.7, 3.2, and 3.9 times more likely to
have had an invasive procedure, at least 1 target joint, or an inhibitor, respectively, during
the year in which the infection occurred. In the multivariate model, severity of haemophilia,
HIV and HCV status were no longer significantly associated with case status.
After adjusting for differences in age, BMI, haemophilia severity, race/ethnicity, the
presence of a target joint, recent invasive surgery, and an inhibitor, the cases had an average
increase in overall ROM limitation of 2.4%, whereas the corresponding value for controls
was only 0.5% (p = 0.04) over a similar period. ROM measures decreased in the infected
joints of 72% of the case patients with an average 11.6% ROM limitation change in the
affected joint vs. 0.6% in that of the contralateral joint (p = 0.052).
DISCUSSION
We found that the incidence of septic arthritis in haemophiliacs is 15–40 times higher than
the reported incidence in the general population, 3–4 times higher than that seen among
people with rheumatoid arthritis, [18–20] and similar to that reported in patients with
prosthetic joints [21, 22], Several factors are likely responsible for the high incidence of
septic arthritis in the haemophilia population, including a higher prevalence of pre-existing
joint damage from repeated hemarthrosis and the high rate of joint replacements performed
in this population.
As reported in other studies [1, 2], increasing age was associated with a higher risk of septic
arthritis in haemophiliacs. We speculate that with increasing age, there is progression in the
degree of joint disease from repeated hemarthrosis, thus setting up the joint for bacterial
seeding. Hemophilic joint disease characterized by chronic synovitis, articular cartilage
damage, and subchondral cysts, may facilitate colonization following intravenous
Ashrani et al. Page 5













cannulation for factor replacement or other sources of transient bacteremia, such as an
invasive orthopedic procedure, which was also associated with a higher incidence of joint
infection in our study. The associations we found between septic arthritis and the presence
of either a target joint or an inhibitor may reflect inadequate treatment of hemarthrosis
leading to prolonged joint exposure to blood, a medium for bacterial growth.
Compared with whites, we found that blacks, Hispanics, and persons of other races were
significantly more likely to develop septic arthritis. The reasons for these differences are not
entirely clear, but it is possible that minorities have decreased access to health care
compared with whites and may also delay seeking medical attention for either hemarthrosis
or localized or systemic infection. Although we accounted for differences in health
insurance type in our analysis, there are other factors that lead to delayed treatment,
including cost, transportation issues, and knowledge and attitudes about illness [23]. These
differences could also reflect residual confounding from other unknown factors that were
not included in the model but we are unaware of other factors that may be related both to
race or ethnicity and the risk of septic arthritis.
Even though the proportion of patients that were HIV positive was higher among cases than
among controls, HIV infection was not an independent risk factor for septic arthritis in our
study. Similarly, in a prospective study of septic arthritis among hospitalized patients in
Africa, a higher proportion of septic arthritis cases were HIV positive compared with a
control group even though there was no difference in the septic arthritis prevalence between
HIV-positive and HIV-negative patients [24]. Much of the evidence for the apparent
association between HIV infection and septic arthritis in haemophilia comes from small case
series in single institutions in which a high proportion of the cases were HIV positive. In
contrast, studies that compared outcomes of surgery in patients with haemophilia found no
difference in infection rates between HIV-positive patients without AIDS and those who
were HIV negative [5, 25, 26].
In our study, the presence of a central venous access device (CVAD), typically used more in
children than in adults for prophylaxis, was not a risk factor for septic arthritis. A somewhat
smaller proportion of cases than controls had a CVAD, and none of the cases had a CVAD
infection at the time of their joint infection. On the other hand, all but one of the cases
infused factor at home. Home infusion, made possible by the advent of factor concentrates,
has been shown to improve quality of life [27] and reduce hospitalizations for bleeding
complications [28]. However, intravenous infusions conducted under less-than-ideal
conditions may increase the risk of infection from improper sterile technique. The majority
of the organisms cultured from our patients were skin pathogens that likely were introduced
during factor infusions. Further evidence for infusions as the source for these infections is
the fact that, among patients infected with HIV, septic arthritis caused by these organisms
occurs among intravenous drug abusers but not among homosexuals [29]. At least one
investigator has proposed that the increasing prevalence of home infusion, not HIV
infection, is responsible for the apparent increase in septic arthritis during the past 2 decades
[8].
In a community-based study of 154 consecutive patients in the Netherlands, the morbidity
associated with septic arthritis was substantial, especially among individuals with pre-
existing joint disease, those with prostheses, and the elderly [30]. In that study, 10% of
patients died and nearly 50% of adults had a poor outcome defined as limb amputation,
removal of prosthesis, or much worse self-reported function of the affected joint. Among 29
patients with an infected prosthesis, 20 (69%) underwent removal of the joint in that series.
In our study, based on joint ROM measurements made during annual visits before and after
the joint infection, we found a 5-fold greater increase in overall ROM limitation among our
Ashrani et al. Page 6













haemophilia patients with septic arthritis than among the control group over a similar period.
The average ROM limitation change in the infected joint was 11.6% vs. 0.6% in that of the
contralateral joint (p = 0.052). These findings provide evidence that the difference between
cases and controls was a result of the septic arthritis. This change in ROM following joint
infection might impact the activities of daily living. Finally, just as in the Dutch study, a
high proportion (77%) of the infected prosthetic joints in our patients with haemophilia
required surgical removal.
Several limitations should be considered when evaluating the results of this study. First, the
septic arthritis cases were initially identified on the basis of a yes response to the data form
screening question “Has the patient had a joint infection during the past year.” As a result of
our second survey for this study, we found that there were more cases of joint infection
reported on the data forms than could be confirmed by objective criteria present in the
medical record. One possible explanation is that the initial response provided on the UDC
data form was based on patient recall rather than by a review of the medical record.
Although we are confident that the cases we report truly did have an infection, it is possible
that other patients who had a joint infection may have been missed since we could not
practically seek confirmation of control status. In addition, to be captured by our
surveillance, patients who had septic arthritis must have survived long enough to have a
clinic visit during which the septic arthritis was reported. Patients who died as a result of
their septic joint would have been missed. For these reasons, we may have underestimated
the rate of septic arthritis in this population. In addition, we did not specifically evaluate the
incidence and risk factors for septic arthritis in female Haemophilia carriers or individuals
with other bleeding disorders.
A second limitation of our study's retrospective design is that concomitant medical issues
that may have contributed to the joint infection may have been overlooked and, therefore,
were not documented in the medical record. Thus, we may have incorrectly specified the
risk factors present for patients, which would have had the overall effect of decreasing the
apparent associations we observed. However, the risk factors that we studied, such as prior
urologic procedures, HIV infection, and CVAD placement, were unlikely to have been
omitted from the medical record.
In conclusion, septic arthritis in an uncommon complication, but it occurs at a higher rate in
individuals with haemophilia than in the general population and may lead to an accelerated
decline in joint range of motion. Age greater than 30 years, history of a recent invasive
procedure, and the presence of either an inhibitor or a target joint were associated with
increased risk for septic arthritis among patients with haemophilia after adjusting for
potential confounders. Our finding of greater risk among minorities warrants further study.
Septic arthritis should be included in the differential diagnosis in patients with haemophilia
with localized joint pain and swelling, especially if there is associated fever and
refractoriness to appropriate factor replacement therapy.
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Table 1
Infected Joint Characteristics
Characteristic Cases (n = 30) Percentage
Joint infected *
 Knee 20 66.7
 Ankle 6 20.0
 Elbow 3 10.0
 Hip 3 10.0
 Wrist 1 3.3
Organism isolated
 Polymicrobial 4 13.3
 Gram positive 23 76.7
  Staphylococcus species 15 50.0
      Staphylococcus aureus 7 23.3
      MRSA 2 6.7
      Staphylococcus coagulase negative 2 6.7
  Streptococcus species 7 23.3
      Streptococcus viridans 3 10.0
      Streptococcus pneumoniae 1 3.3
      Beta hemolytic streptococcus 1 3.3
      Enterococcus faecalis 1 3.3
      Streptococcus bovis 1 3.3
  Gram positive bacilli 1 3.3
 Gram negative 6 20.0
    Escherichia coli 2 6.7
    Enterobacter cloacae 1 3.3
    Pseudomonas aeruginosa 2 6.7
    Serratia marcescens 1 3.3
 Filamentous fungi 1 3.3
  Prior joint surgery 18 60.0
  Joint replacement 13 43.3
  Synovectomy 2 6.7
  Debridement 1 3.3
  Fusion 2 6.7
 Recent joint aspiration of the affected joint 2 6.7
 Recent trauma of the affected joint 2 6.7
*
2 patients had an infection in more than one joint
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Table 3
Independent risk factors for a joint infection among males with haemophilia based on multivariate analysis.
Risk factor OR 95% CI p-value
Age (30–39 vs <30 years) 6.1 2.1 – 17.9 0.001
Age (40+ vs <30 years) 9.4 3.7 – 23.8 <0.001
Black race (vs white) 5.0 2.1 – 11.9 <0.001
Hispanic (vs white) 3.9 1.3 – 11.4 0.01
Other race (vs white) 4.5 1.2 – 16.3 0.02
Invasive procedure 2.7 1.1 – 6.4 0.03
At least 1 target joint 3.2 1.5 – 6.8 0.004
Inhibitor 3.9 1.5 – 9.9 0.004
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